Gabapentin
Product Images NDC 50090-5125

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50090-5125). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

The image shows a formula for calculating creatinine clearance (CLCr). It includes variables for age (years), weight (kg), serum creatinine (mg/dL), and a multiplication factor of 0.85 for female patients.*

FDA Label Image

Gabapentin Fig1

A line graph comparing mean pain scores over 8 weeks between placebo and Gabapentin 3600 mg/day groups. The x-axis shows weeks from baseline to week 8, and the y-axis shows mean pain score from 0 to 10. The graph indicates a 4-week dose titration period followed by a 4-week fixed dose period, with the Gabapentin group showing a decreasing pain score trend compared to placebo.*

FDA Label Image

Gabapentin Fig2

A line graph depicting mean pain scores over a 7-week period comparing placebo and two dosages of Gabapentin (1800 mg/day and 2400 mg/day). The x-axis represents weeks from baseline to week 7, with a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis shows the mean pain score ranging from 0 to 10. Gabapentin groups show a greater reduction in mean pain scores compared to placebo over time.*

FDA Label Image

Gabapentin Fig3

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies'. It compares response rates between placebo (PBO) and different doses of Gabapentin (GBP 3600 mg, 1800 mg, and 2400 mg) across two studies. Study 1 shows 12% response for placebo and 29% for GBP 3600. Study 2 shows 14% for placebo, 32% for GBP 1800, and 34% for GBP 2400. Statistical significance is indicated (p < 0.01 and p < 0.001).*

FDA Label Image

Gabapentin-fig4 (Gabapentin Fig4)

A scatter plot chart comparing difference percentages by daily dose (mg) for Gabapentin across three studies labeled a, b, and c. The X-axis represents daily dose ranging approximately from 600 to 1800 mg, while the Y-axis shows the difference percentage ranging from 2% to 22%. Study a data points are solid black squares, study b are gray squares, and study c is a white square.*

FDA Label Image

Gabapentin-struc (Gabapentin Struc)

Chemical structure diagram of the active ingredient gabapentin, showing its cyclohexane ring and amino and carboxyl functional groups.*

FDA Label Image

Label Image (Lbl500905125)

Gabapentin 100 mg capsules label from A-S Medication Solutions with product NDC 50090-5125. The label states each capsule contains 100 mg gabapentin USP, storage instructions at 68 to 77 degrees Fahrenheit, and package size of 33 units. Manufacturer information includes Alkem Laboratories Ltd. and batch details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.